Últimas noticias sobre SoFi Techs (NASDAQ:SOFI) Bolsa

SoFi Techs

SoFi is a financial-services company that was founded in 2011 and is based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020, the company also offers payment and account services for debit cards and digital banking.

SoFi Technologies

SoFi Technologies Inc

RAI Finance

SoFi Next 500 ETF

SoFi Select 500 ETF

SoFi Social 50 ETF

Sofina SA

-- The Simple, No-cost Test Can Detect Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Autoantibodies in the Blood with Only a Finger Prick --
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54219866&amp;newsitemid=20250306574544&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=7869700ed793696d9f0296d20b4454f8">Savara Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRA#NASDAQ">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the U.S., an evolution of the first serum-based assay the Company launched. The DBS test helps obtain a diagnosis of aPAP, a rare autoimmune lung disease caused by antibodies targeting GM-CSF, with only a finger-prick blood sample.
The DBS test demonstrates a high correlation between GM-CSF autoantibody levels in dried serum and traditional serum samples, ensuring reliable results, and has achieved 100% analytical sensitivity and specificity in a cohort of individuals with confirmed GM-CSF autoantibody status. The Company partnered with TrilliumBiO, a health solutions provider with a Clinical Laboratory Improvement Amendments (CLIA)-certified lab, to develop and validate the simple, no-cost, and noninvasive test.

Biotech

News

General

SVRA

Savara Announces U.S. Launch Of The aPAP ClearPath Dried Blood Spot Test To Detect Autoimmune Pulmonary Alveolar Proteinosis

Piper Sandler analyst Mark Lear maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Neutral and raises the price target from $96 to $101.

Price Target

Analyst Ratings

Piper Sandler Maintains Neutral on Expand Energy, Raises Price Target to $101

&nbsp;
- ARO-INHBE and ARO-ALK7 both target a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies
- Data highlight Arrowhead's leadership in the use of RNA interference to potentially treat Obesity

Events

ARWR

Arrowhead Pharmaceuticals Presents Preclinical Data Supporting ARO-INHBE and ARO-ALK7 To Treat Obesity And Metabolic Diseases

Piper Sandler analyst Mark Lear maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Neutral and raises the price target from $35 to $36.

Piper Sandler Maintains Neutral on EQT, Raises Price Target to $36

WIIM

Ohmyhome shares are trading lower after the company announced a 1-for-10 reverse stock split to be effective on March 10.

Explore what deepfake creators are doing to evade detection, the impact of generative AI on deepfakes, the escalating threats in cybersecurity, and mitigation tactics to combat AI-driven fraud
DENVER, March 06, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=rFOHMcqj_xFshal7LipmCBFFFJt5e8DlWGtVp-ynloq1_reYS16SU_A_1imtT7IO">authID</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>), a leading provider of biometric identity verification and authentication solutions, today released a comprehensive whitepaper detailing innovative approaches to combat the rising threat of deepfake fraud in digital authentication systems. The whitepaper, titled "Deepfake Countermeasures," provides crucial insights into deepfakes as the next generation in fraud attacks, as well as cutting-edge defensive strategies against presentation and injection attacks.
The increasing sophistication of AI platforms means attackers can use a single photo to synthesize deepfake videos. authID's report presents a critical framework for organizations to protect against a spike in identity fraud attempts and leverages authID's proprietary multi-layered detection system, which achieves a billion-to-one false-match accuracy rate. authID's platform detects the liveness of each authentication attempt, preventing the use of pictures, videos and deepfakes for spoofing identities, known as presentation attacks.

AUID

authID Publishes New Whitepaper On Next-Generation Deepfake Detection Technology Titled "Deepfake Countermeasures"

CYCU

Cycurion Partners With CentralSquare Technologies To Provide Public Safety IT Services

Piper Sandler analyst Mark Lear maintains EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Neutral and lowers the price target from $141 to $135.

Piper Sandler Maintains Neutral on EOG Resources, Lowers Price Target to $135

ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>, or "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, today announced that it has entered into a securities purchase agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of 2,105,265 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,105,265 shares of common stock at an effective combined price of $0.95 per share and common warrant for aggregate gross proceeds of approximately $2.0 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $1.00 per share, will be exercisable immediately upon shareholder approval and will expire five years from the initial exercise date.
The closing of the offering is expected to occur on or about March 7, 2025, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering for general working capital.
A.G.P./Alliance Global Partners is acting as the sole placement agent in connection with the transaction.

Offerings

ZVSA

ZyVersa Therapeutics Announces Pricing Of $2M Private Placement Priced At The Market

Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features&nbsp; of Systemic Sclerosis &nbsp;
TEL AVIV, Israel, March 06, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=7iF72dYqYIForA9mYcGm2LioRkwJo-D8darEBq2CyCSJdVooMoRIrOJIfUAPi3gadSYKb144QxsjXCtgJMQWuMo1xSfGTSctxDdvzOyvSgM=">Chemomab Therapeutics, Ltd</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced a new scientific presentation that further confirms the potential of nebokitug (CM-101) as a novel treatment for systemic sclerosis (SSc).1 The data will be presented at the <a href="https://www.globenewswire.com/Tracker?data=96J9V9lZEEXaaV4s9q1tzEexR1fMKSwwgereOBqnmCVF1xwKqCBsiRcUvSGYYD1NBd2mwDXtXUDcoHSH_MojM8L6_L5OYnR2XA0hBT0Y_9VKzH0WWY013rp0cutDL663VkqvKwTzSCweluKIY4Hmp9LDhTDoyO3UmPZLfVh_Bkg=">8th International Congress on Controversies in Rheumatology and Autoimmunity</a> (CORA 2025) on March 8, 2025, in Venice, Italy.
Systemic sclerosis is an autoimmune disease characterized by microvascular injury and extensive tissue fibrosis of the skin and internal organs. It is the most lethal of the systemic connective tissue diseases and lacks approved disease-modifying therapies. Nebokitug is a first-in-class monoclonal antibody that blocks the soluble protein CCL24, which has been shown to be a key driver of the pathways underlying fibro-inflammatory conditions such as SSc and primary sclerosing cholangitis (PSC). In extensive preclinical studies, blocking CCL24 reduced the inflammatory and fibrotic injury to the lung, skin and vasculature that are hallmarks of SSc pathology. An investigator-sponsored study showed that treatment with nebokitug induced strong and rapid reductions in inflammatory biomarkers in patients with acute lung Injury, a relevant model for the type of lung damage seen in SSc patients.

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

Chemomab Therapeutics Presents New Data Highlighting Clinical Potential Of Its Nebokitug In Systemic Sclerosis At CORA 2025 Conference

Lakeside Holding shares are trading higher after the company announced convertible debt financing of up to $4.5 million.

Piper Sandler analyst Mark Lear maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Overweight and raises the price target from $34 to $37.

CTRA

Piper Sandler Maintains Overweight on Coterra Energy, Raises Price Target to $37

Guidance

Macy's CEO Says Consumers Remain Under Pressure Navigating From An Inflation Rate And Yet Wanting To Indulge At Times; Says 'I Don't Think The Consumer Is Going To Feel A Sense Of Relief In The Short Term'

<ul>
<li>Proactive steps reinforce bioAffinity Technologies' laser focus on accelerating CyPath&#xAE; Lung sales growth in strategic national markets</li>
<li>Decreases labor and overhead costs, including 38% workforce reduction in non-CyPath&#xAE; Lung personnel at Company's subsidiary laboratory</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbioaffinitytech.com%2F&amp;esheet=54220116&amp;newsitemid=20250306388376&amp;lan=en-US&amp;anchor=bioAffinity+Technologies&amp;index=1&amp;md5=35df396edda935fc0a25014d8944a15f">bioAffinity Technologies</a>, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>, BIAFW)), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced targeted strategic actions to improve financial performance and accelerate the commercial growth of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cypathlung.com&amp;esheet=54220116&amp;newsitemid=20250306388376&amp;lan=en-US&amp;anchor=CyPath%26%23174%3B+Lung&amp;index=2&amp;md5=a255ade8a66b4dc2743693184fe3bafd">CyPath&#xAE; Lung</a>, the Company's noninvasive test for early-stage lung cancer. The Company expects these measures to deliver approximately $4 million in annual cost savings at its subsidiary Precision Pathology Laboratory Services (PPLS), while increasing resources to expand CyPath&#xAE; Lung sales in high-potential national markets.

BIAF

bioAffinity Technologies Announces Targeted Strategic Actions To Improve Financial Performance And Accelerate The Commercial Growth Of CyPath Lung; Expects These Measures To Deliver ~$4M In Annual Cost Savings

Macy's CFO Says For Q1 Expect These Pressures Along With Inflation And Tariffs To Continue

ONVO

Organovo shares are trading higher after the company announced issuance of additional shares.

Piper Sandler analyst Mark Lear maintains Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>) with a Overweight and lowers the price target from $71 to $66.

CIVI

Piper Sandler Maintains Overweight on Civitas Resources, Lowers Price Target to $66

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/06063601/CSPC-PharmaW.png" alt="" class="wp-image-7261" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/06063601/CSPC-PharmaW.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/06063601/CSPC-PharmaW-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/06063601/CSPC-PharmaW-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The generic drugs giant has warned of a 26% slide in annual profits after China's national healthcare system imposed big price cuts on qualifying medicines

<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>CSPC Pharma was already on track for a tough earnings season after its nine-month profits fell 15.9%</li>
<li>Another blow was the sudden departure of the firm's head of innovative drug research, Liu Yongjun, a well-known industry figure</li>
</ul>
Is the gloss coming off the crown for one of the kings of China's drugs industry?
A profit warning late last month from drugs giant&nbsp;CSPC Pharmaceutical Group Ltd.&nbsp;(1093.HK) does beg the question. After enjoying growing sales of cancer drugs and antibiotics, the company is now facing a steep drop in its&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0225/2025022500951.pdf">full-year profits</a>, hit by price controls for its signature products under China's national healthcare system.
After the market close on February 25, CSPC Pharma said it expected its net profit for 2024 to have fallen about 26% from the 5.87 billion yuan ($807 million) it earned in 2023. The drop was blamed on a 7% decline in takings from the finished drug business, the main pillar of the company's earnings.
Finished drugs brought in 13.55 billion yuan, 83% of total revenue, in the first half of 2024. CSPC Pharma, one of four so-called kings of the Chinese generic drugs business, also sells raw materials for antibiotics, vitamin C products and other supplements.
In the statement, CSPC Pharma blamed its earnings slide on China's centralized drug procurement process, which had slashed the prices of key products. A drug used to elevate white blood cells during chemotherapy had its price cut by 58% under the bulk deal. Another CSPC Pharma drug for lymphoma and breast or ovarian cancer was discounted by 23% in the same procurement round, the company said.
Sales of these two star products, Jinyouli and Duomeisu, have been falling since the bulk purchasing policy was gradually rolled out across Chinese regions over the past year, the company said. The revenue from oncology therapeutics therefore plunged around 28% in 2024 compared with the prior year.
Any products knocked out of the bulk bidding will not suffer big price cuts, but losing access to this centrally coordinated market would also take its toll on earnings. CSPC Pharma pointed out that sales of Xuanning, a drug for hypertension and angina, had fallen sharply in hospitals that had adopted the new system, after the product failed to be selected in a procurement round in 2023. As a result, revenue from the cardiovascular therapeutic area fell approximately 15% in 2024 from the previous year.
Pitching competitive bids for national health contracts is a key revenue factor for a company like CSPC Pharma, which produces a wide range of generic drugs. Fifteen of its products were selected in the latest national procurement round. Eight of the winning CSPC Pharma bids were the cheapest in the mix, according to details that emerged from a meeting last December of the national purchasing agency. As well as the price, the body also took the firm's high-tech manufacturing capability and in-house production of active pharmaceutical ingredients into account, judging that CSPC Pharma could deliver quality products even at the cheaper rate.
In fact, CSPC Pharma was already heading for a weak full-year result. Its operating revenue rose just 1.3% to 6.28 billion yuan in the first half of 2024, for a net profit of 3.2 billion yuan. &nbsp;Given that profits for the first nine months fell 15.9%, the slide must have accelerated in the fourth quarter to justify the latest full-year projection.
<h4 class="wp-block-heading">Developing new drugs</h4>
In recent years, many veteran suppliers of generic drugs have been shifting their focus to emerging treatments, partly to offset central procurement's bargaining power. One of the other "four kings",&nbsp;Hengrui Pharmaceuticals&nbsp;(600276.SH), is taking the lead in moving up the value chain to produce innovative drugs. Hengrui's profits shrank for two straight years before it managed to offset the procurement squeeze in 2023. Since then, Hengrui has returned to earnings growth on the back of its novel drug business.
CSPC Pharma has also been investing heavily in innovative drug research and development since 2018, although most of the resulting compounds are still at the clinical trial stage. The candidate drugs include mRNA vaccines and targeted therapies using antibody drug conjugates (ADCs) as well as monoclonal or bispecific antibodies.
So far only three of the drugs have been approved for sale, and the new pipelines will not make up for lost revenue from discounted generics in the health program. In its half-year results for 2024, the company said it had around 60 key drugs under development, of which seven have been submitted for marketing approval and 19 are still entering the clinical stage.
The challenges have been compounded by executive changes. Last September, CSPC Pharma welcomed a new head of global R&amp;D who had previously worked for Innovent and had built up standing in the industry. Liu Yongjun was given a brief to speed up the development program, but he left suddenly after just three months in the job, raising concerns about the pace of progress towards a portfolio of advanced drugs.
On the positive side, the company has also entered into a series of licensing deals. Most Chinese companies keep hold of the domestic market when they sell marketing rights to new or candidate drugs, but CSPC is taking a different approach. Its latest agreements transfer global rights including Greater China to its partners, suggesting the company may intend to specialize in the preliminary phase of R&amp;D.
Global development and sales rights for a potential lipid-lowering therapy as well as experimental drugs for a variety of cardiovascular diseases were sold to&nbsp;AstraZeneca&nbsp;(AZN.US) in October last year. The deal gives CSPC Pharma up to $2 billion, including a down payment of $100 million (729 million yuan). Two months later the drug giant licensed out its global interests in a drug for cancers with a gene mutation known as MAT2A to&nbsp;BeiGene&nbsp;(6160.HK, BGNE.US). CSPC Pharma gets an upfront fee of up to $150 million, development payments of up to $135 million and further fees of up to $1.55 billion if it hits sales milestones, as well as royalties.
The income from those deals should burnish CSPC Pharma's results, but at the cost of lucrative benefits down the road if the drugs eventually go on sale. The firm currently trades at a price-to-earnings (P/E) ratio of just 10 times, far lower than the 54 times for Hengrui Pharmaceuticals. The company's stock has slipped since the profit warning, but the price remains virtually flat for the year to date.
With underwhelming earnings, CSPC Pharma will need to show swift progress on innovative drugs if it wants to inspire more confidence among investors.

Asia

Health Care

CSPC Pharma's Earnings Hit By China's Drug Price Control Measures

Macy's CFO Says There Were Some Unexpected Factors In The Early Part Of The Quarter With The Fires And Cold Weather That Impacted Results

Piper Sandler analyst Mark Lear maintains Chord Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>) with a Overweight and lowers the price target from $193 to $184.

CHRD

Piper Sandler Maintains Overweight on Chord Energy, Lowers Price Target to $184

Press Releases

10 Million Members Now Getting Their Money Right with SoFi

SoFi Schedules Conference Call to Discuss Q4 2024 & Full Year 2024 Results

SoFi and PGIM Fixed Income Announce $525 Million Securitization Agreement, Signaling Continued Demand for Personal Loans

SoFi Technologies Reports Net Revenue of $734 Million and Net Income of $332 Million for Q4 2024, Demonstrating Durable Growth and Strong Returns

SoFi to Participate in Upcoming Investor Conference

Ticker Tape Investments Leads Series C Funding Round for Utility Rescue Holdings, Inc.

SoFi Plus Premium Membership Now Offers $1,000+ in Annual Value

Galileo Financial Technologies Enables Brands to Offer Co-Brand Debit Rewards Cards

Fintech

Ascenda and Galileo Financial Technologies Collaborate to Elevate Card Loyalty Programs

SoFi Closes $697.6 Million Securitization of Loan Platform Business Volume

PLTR

SOFI

Ally Financial

American Express

Bread Financial Holdings, Inc. Common Stock

Bread Finl Hldgs

Credit Acceptance Corporation - Common Stock

Credit Acceptance

Capital One Financial Corporation Common Stock

Capital One Finl

Dave

Discover Financial servs

Encore Capital Gr

Enova International

FirstCash Hldgs

FinVolution Group American Depositary Shares

FinVolution Gr

Joint Stock Company Kaspi.kz - American Depository Shares

Kaspi.kz

LendingClub

Lufax Holding Ltd American Depositary Shares, each representing two (2) Ordinary Shares

Comments

SoFi Techs

Noticias

Últimas noticias sobre SoFi Techs (NASDAQ:SOFI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL